437 related articles for article (PubMed ID: 21651476)
1. ATP-competitive inhibitors of mTOR: an update.
Schenone S; Brullo C; Musumeci F; Radi M; Botta M
Curr Med Chem; 2011; 18(20):2995-3014. PubMed ID: 21651476
[TBL] [Abstract][Full Text] [Related]
2. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.
Lv X; Ma X; Hu Y
Expert Opin Drug Discov; 2013 Aug; 8(8):991-1012. PubMed ID: 23668243
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
[TBL] [Abstract][Full Text] [Related]
4. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
[TBL] [Abstract][Full Text] [Related]
5. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.
Zask A; Verheijen JC; Richard DJ
Expert Opin Ther Pat; 2011 Jul; 21(7):1109-27. PubMed ID: 21591993
[TBL] [Abstract][Full Text] [Related]
7. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
[TBL] [Abstract][Full Text] [Related]
8. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.
García-Echeverría C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4308-12. PubMed ID: 20561789
[TBL] [Abstract][Full Text] [Related]
9. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
10. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Yuan J; Mehta PP; Yin MJ; Sun S; Zou A; Chen J; Rafidi K; Feng Z; Nickel J; Engebretsen J; Hallin J; Blasina A; Zhang E; Nguyen L; Sun M; Vogt PK; McHarg A; Cheng H; Christensen JG; Kan JL; Bagrodia S
Mol Cancer Ther; 2011 Nov; 10(11):2189-99. PubMed ID: 21750219
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
12. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
13. Current treatment strategies for inhibiting mTOR in cancer.
Chiarini F; Evangelisti C; McCubrey JA; Martelli AM
Trends Pharmacol Sci; 2015 Feb; 36(2):124-35. PubMed ID: 25497227
[TBL] [Abstract][Full Text] [Related]
14. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
15. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
16. Updates of mTOR inhibitors.
Zhou H; Luo Y; Huang S
Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
[TBL] [Abstract][Full Text] [Related]
17. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
18. Role of mTOR Inhibitors in Kidney Disease.
Kajiwara M; Masuda S
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338360
[TBL] [Abstract][Full Text] [Related]
19. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations.
Moschetta M; Reale A; Marasco C; Vacca A; Carratù MR
Br J Pharmacol; 2014 Aug; 171(16):3801-13. PubMed ID: 24780124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
